Ipranour-L Junior Respules contain a combination of Levosalbutamol 0.63 mg and Ipratropium 500 mcg, formulated for pediatric patients requiring bronchodilator therapy. Levosalbutamol, a selective β2-adrenergic receptor agonist, acts by relaxing bronchial smooth muscle, resulting in bronchodilation and relief from bronchospasm associated with asthma and other obstructive airway diseases. Ipratropium, an anticholinergic agent, inhibits muscarinic receptors in the airways, reducing bronchoconstriction and mucus secretion. The synergistic action of these agents provides rapid and sustained bronchodilation, improving airflow and reducing respiratory distress in conditions such as bronchial asthma, chronic obstructive pulmonary disease (COPD), and bronchiolitis in children. Ipranour-L Junior Respules are administered via nebulization, ensuring direct delivery to the respiratory tract for prompt therapeutic effect. This combination is particularly useful in pediatric patients who require effective management of acute bronchospasm unresponsive to monotherapy. The dosage and duration of therapy should be individualized based on clinical response and severity of symptoms. Caution is advised in patients with hypersensitivity to either component, and monitoring for potential side effects such as tachycardia, dry mouth, or tremors is recommended.